204 related articles for article (PubMed ID: 8536813)
1. Similarities and differences in the properties of substituted benzimidazoles: a comparison between pantoprazole and related compounds.
Kromer W
Digestion; 1995; 56(6):443-54. PubMed ID: 8536813
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics, metabolism and interactions of acid pump inhibitors. Focus on omeprazole, lansoprazole and pantoprazole.
Andersson T
Clin Pharmacokinet; 1996 Jul; 31(1):9-28. PubMed ID: 8827397
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics and effect on caffeine metabolism of the proton pump inhibitors, omeprazole, lansoprazole, and pantoprazole.
Andersson T; Holmberg J; Röhss K; Walan A
Br J Clin Pharmacol; 1998 Apr; 45(4):369-75. PubMed ID: 9578184
[TBL] [Abstract][Full Text] [Related]
4. The H+, K(+)-ATPase inhibitor pantoprazole (BY1023/SK&F96022) interacts less with cytochrome P450 than omeprazole and lansoprazole.
Simon WA; Büdingen C; Fahr S; Kinder B; Koske M
Biochem Pharmacol; 1991 Jul; 42(2):347-55. PubMed ID: 1650212
[TBL] [Abstract][Full Text] [Related]
5. Metabolic interactions of the proton-pump inhibitors lansoprazole, omeprazole and pantoprazole with other drugs.
Meyer UA
Eur J Gastroenterol Hepatol; 1996 Oct; 8 Suppl 1():S21-5. PubMed ID: 8930576
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of omeprazole, lansoprazole, pantoprazole, and rabeprazole in the treatment of acid-related diseases.
Welage LS; Berardi RR
J Am Pharm Assoc (Wash); 2000; 40(1):52-62; quiz 121-3. PubMed ID: 10665250
[TBL] [Abstract][Full Text] [Related]
7. Acid suppression in healthy subjects following lansoprazole or pantoprazole.
Huang JQ; Goldwater DR; Thomson AB; Appelman SA; Sridhar S; James CF; Chiu YL; Pilmer BL; Keith RG; Hunt RH
Aliment Pharmacol Ther; 2002 Mar; 16(3):425-33. PubMed ID: 11876695
[TBL] [Abstract][Full Text] [Related]
8. Comparative pharmacokinetic/pharmacodynamic analysis of proton pump inhibitors omeprazole, lansoprazole and pantoprazole, in humans.
Katashima M; Yamamoto K; Tokuma Y; Hata T; Sawada Y; Iga T
Eur J Drug Metab Pharmacokinet; 1998; 23(1):19-26. PubMed ID: 9625268
[TBL] [Abstract][Full Text] [Related]
9. Effects on 24-hour intragastric pH: a comparison of lansoprazole administered nasogastrically in apple juice and pantoprazole administered intravenously.
Freston J; Chiu YL; Pan WJ; Lukasik N; Täubel J
Am J Gastroenterol; 2001 Jul; 96(7):2058-65. PubMed ID: 11467632
[TBL] [Abstract][Full Text] [Related]
10. Comparison of inhibitory effects of the proton pump-inhibiting drugs omeprazole, esomeprazole, lansoprazole, pantoprazole, and rabeprazole on human cytochrome P450 activities.
Li XQ; Andersson TB; Ahlström M; Weidolf L
Drug Metab Dispos; 2004 Aug; 32(8):821-7. PubMed ID: 15258107
[TBL] [Abstract][Full Text] [Related]
11. Interaction of omeprazole, lansoprazole and pantoprazole with P-glycoprotein.
Pauli-Magnus C; Rekersbrink S; Klotz U; Fromm MF
Naunyn Schmiedebergs Arch Pharmacol; 2001 Dec; 364(6):551-7. PubMed ID: 11770010
[TBL] [Abstract][Full Text] [Related]
12. Effects of pantoprazole on xenobiotic metabolizing enzymes in rat liver microsomes: a comparison with other proton pump inhibitors.
Masubuchi N; Hakusui H; Okazaki O
Drug Metab Dispos; 1997 May; 25(5):584-9. PubMed ID: 9152597
[TBL] [Abstract][Full Text] [Related]
13. Review article: the continuing development of proton pump inhibitors with particular reference to pantoprazole.
Huber R; Kohl B; Sachs G; Senn-Bilfinger J; Simon WA; Sturm E
Aliment Pharmacol Ther; 1995 Aug; 9(4):363-78. PubMed ID: 8527612
[TBL] [Abstract][Full Text] [Related]
14. Pharmacodynamic comparison of pantoprazole enantiomers: inhibition of acid-related lesions and acid secretion in rats and guinea-pigs.
Cao H; Wang MW; Sun LX; Ikejima T; Hu ZQ; Zhao WH
J Pharm Pharmacol; 2005 Jul; 57(7):923-7. PubMed ID: 15969954
[TBL] [Abstract][Full Text] [Related]
15. Twenty-four-hour intragastric pH profiles and pharmacokinetics following single and repeated oral administration of the proton pump inhibitor pantoprazole in comparison to omeprazole.
Hartmann M; Theiss U; Huber R; Lühmann R; Bliesath H; Wurst W; Lücker PW
Aliment Pharmacol Ther; 1996 Jun; 10(3):359-66. PubMed ID: 8791964
[TBL] [Abstract][Full Text] [Related]
16. Lack of drug interaction between omeprazole, lansoprazole, pantoprazole and theophylline.
Dilger K; Zheng Z; Klotz U
Br J Clin Pharmacol; 1999 Sep; 48(3):438-44. PubMed ID: 10510158
[TBL] [Abstract][Full Text] [Related]
17. Selective inhibition of the gastric H+,K(+)-ATPase by omeprazole and related compounds.
Lorentzon P; Bayati A; Lee H; Andersson K
Ann N Y Acad Sci; 1997 Nov; 834():592-9. PubMed ID: 9405870
[No Abstract] [Full Text] [Related]
18. Twenty-four-hour monitoring of intragastric acidity: comparison between lansoprazole 30mg and pantoprazole 40mg.
Florent C; Forestier S
Eur J Gastroenterol Hepatol; 1997 Feb; 9(2):195-200. PubMed ID: 9058634
[TBL] [Abstract][Full Text] [Related]
19. Different effects of short-term omeprazole, lansoprazole or pantoprazole on the accuracy of the (13)C-urea breath test.
Parente F; Sainaghi M; Sangaletti O; Imbesi V; Maconi G; Anderloni A; Bianchi Porro G
Aliment Pharmacol Ther; 2002 Mar; 16(3):553-7. PubMed ID: 11876710
[TBL] [Abstract][Full Text] [Related]
20. Differences in pH-dependent activation rates of substituted benzimidazoles and biological in vitro correlates.
Kromer W; Krüger U; Huber R; Hartmann M; Steinijans VW
Pharmacology; 1998 Feb; 56(2):57-70. PubMed ID: 9494064
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
